Sangamo Therapeutics, INC Form 4 insider transactions

Nathalie Dubois-Stringfellow, SVP-Chief Development Officer of Sangamo Therapeutics, sold shares to cover tax obligations following the vesting of a restricted stock unit (RSU) grant.

Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics, disposed of shares to cover tax obligations related to vested restricted stock units.

Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics, reports the acquisition and disposition of company stock related to RSU vesting and tax withholding.

Nathalie Dubois-Stringfellow, SVP-Chief Development Officer at Sangamo Therapeutics, reports acquisition and disposal of common stock and stock options related to vesting of restricted stock units and tax withholding.

Scott B. Willoughby, SVP, General Counsel & Secretary of Sangamo Therapeutics, reports stock transactions including vesting of restricted stock units and associated tax withholding.

Prathyusha Duraibabu, CFO of Sangamo Therapeutics, reports disposition of shares for tax withholding purposes following RSU vesting, along with the grant of new stock options and RSUs.

CEO Sandy Macrae reports disposition of shares for tax withholding and acquisition of shares through RSU grants and stock options.

Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics, sold shares to cover tax obligations following the vesting of a restricted stock unit (RSU) grant.

Nathalie Dubois-Stringfellow, SVP-Chief Development Officer of Sangamo Therapeutics, sold shares to cover tax obligations related to vested restricted stock units.

Scott Willoughby, SVP, General Counsel & Secretary of Sangamo Therapeutics, reports disposition of shares for tax withholding purposes related to RSU vesting.

Prathyusha Duraibabu, SVP and CFO of Sangamo Therapeutics, reports the disposal of shares to cover tax obligations upon vesting of restricted stock units.

CEO Sandy Macrae disposed of shares to cover tax obligations related to vested restricted stock units (RSUs).

Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics, disposed of shares to cover tax obligations related to vesting restricted stock units.

A Sangamo Therapeutics executive, Scott B. Willoughby, sold shares to cover tax obligations following the vesting of restricted stock units.

Nathalie Dubois-Stringfellow, SVP-Chief Development Officer at Sangamo Therapeutics, sold shares to cover tax obligations following the vesting of restricted stock units.

Sangamo Therapeutics' Chief Financial Officer, Prathyusha Duraibabu, sold shares to cover tax obligations following the vesting of restricted stock units.

Sangamo Therapeutics CEO, Sandy Macrae, disposed of shares to cover tax obligations following the vesting of restricted stock units.

Scott B. Willoughby, SVP, General Counsel & Secretary of Sangamo Therapeutics, reports disposition of shares to cover tax obligations related to RSU vesting.

Amy Pooler, VP at Sangamo Therapeutics, reports disposition of shares to cover tax obligations related to RSU vesting, with no discretionary trading involved.

Prathyusha Duraibabu, CFO of Sangamo Therapeutics, reports disposition of shares to cover tax obligations related to vesting restricted stock units (RSUs).

Nathalie Dubois-Stringfellow, SVP-Chief Development Officer at Sangamo Therapeutics, reports disposition of shares to cover tax obligations upon RSU vesting, while still holding a significant number of shares.

CEO Sandy Macrae disposed of shares to cover tax obligations related to vesting restricted stock units (RSUs).

Scott B. Willoughby, SVP, General Counsel & Secretary of Sangamo Therapeutics, surrendered shares to cover tax obligations upon vesting of a restricted stock unit.

Prathyusha Duraibabu, SVP and CFO of Sangamo Therapeutics, reports a transaction involving the surrender of shares for tax withholding purposes related to vested Restricted Stock Units (RSUs).

Director Karen L. Smith reports acquisition of 25,000 shares of common stock and 50,000 stock options in Sangamo Therapeutics.

Director H Stewart Parker acquired 25,000 shares of common stock and options to purchase 50,000 shares of Sangamo Therapeutics.

Director James R. Meyers acquired 25,000 shares of common stock and options to purchase 50,000 shares of Sangamo Therapeutics stock on June 4, 2024.

Director John Markels acquired 25,000 shares of common stock and 50,000 stock options in Sangamo Therapeutics on June 4, 2024.

Director Margaret Horn reports acquisition of 25,000 shares of common stock, 50,000 stock options, and disposition of shares.

Director Kenneth J. Hillan reports acquisition of 25,000 shares of common stock and 50,000 stock options in Sangamo Therapeutics.